News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rallybio Corporaton
(NQ:
RLYB
)
1.150
-0.040 (-3.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Rallybio Corporaton
< Previous
1
2
3
Next >
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
August 29, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences
August 27, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
July 09, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
June 17, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
May 07, 2024
From
Rallybio Corporation
Via
Business Wire
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
April 17, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
April 10, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
April 01, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
February 06, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
January 04, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
December 20, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
December 09, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
November 28, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences in November
November 08, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
November 02, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
October 03, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
September 03, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences in September
August 31, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
August 02, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
July 11, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
June 29, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
June 24, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
June 09, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Rallybio Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.